Press releases & news
The PARP inhibitor Olaparib significantly improves the five-year survival of patients with newly diagnosed advanced ovarian cancer.
Results from the first double-blinded randomized phase III-trial (SOLO-1) between the PARP inhibitor Olaparib and standard chemotherapy showed a clear...
2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark|
Phone: +45 2211 5399|